MoonLake Immunotherapeutics (MLTX)
17.69
+0.20
(+1.14%)
USD |
NASDAQ |
Jun 11, 16:00
17.41
-0.28
(-1.58%)
After-Hours: 18:28
MoonLake Immunotherapeutics Enterprise Value : 1.005B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 1.005B |
| June 09, 2026 | 1.027B |
| June 08, 2026 | 1.041B |
| June 05, 2026 | 1.034B |
| June 04, 2026 | 1.093B |
| June 03, 2026 | 1.061B |
| June 02, 2026 | 1.032B |
| June 01, 2026 | 1.100B |
| May 29, 2026 | 1.126B |
| May 28, 2026 | 1.090B |
| May 27, 2026 | 1.098B |
| May 26, 2026 | 1.085B |
| May 22, 2026 | 1.082B |
| May 21, 2026 | 1.103B |
| May 20, 2026 | 998.02M |
| May 19, 2026 | 947.97M |
| May 18, 2026 | 953.12M |
| May 15, 2026 | 1.035B |
| May 14, 2026 | 1.097B |
| May 13, 2026 | 1.098B |
| May 12, 2026 | 1.082B |
| May 11, 2026 | 1.130B |
| May 08, 2026 | 998.76M |
| May 07, 2026 | 1.009B |
| May 06, 2026 | 1.046B |
| Date | Value |
|---|---|
| May 05, 2026 | 995.08M |
| May 04, 2026 | 1.036B |
| May 01, 2026 | 974.47M |
| April 30, 2026 | 936.20M |
| April 29, 2026 | 916.53M |
| April 28, 2026 | 956.60M |
| April 27, 2026 | 970.44M |
| April 24, 2026 | 994.48M |
| April 23, 2026 | 976.27M |
| April 22, 2026 | 997.40M |
| April 21, 2026 | 997.40M |
| April 20, 2026 | 1.046B |
| April 17, 2026 | 1.079B |
| April 16, 2026 | 1.039B |
| April 15, 2026 | 1.056B |
| April 14, 2026 | 1.111B |
| April 13, 2026 | 1.086B |
| April 10, 2026 | 1.051B |
| April 09, 2026 | 1.157B |
| April 08, 2026 | 1.093B |
| April 07, 2026 | 982.99M |
| April 06, 2026 | 975.73M |
| April 02, 2026 | 1.003B |
| April 01, 2026 | 942.33M |
| March 31, 2026 | 1.087B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BeOne Medicines Ltd. | 24.18B |
| AC Immune SA | 127.97M |
| CRISPR Therapeutics AG | 3.111B |
| Idorsia Ltd. | 2.960B |
| ADC Therapeutics SA | 25.54M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.71M |
| Total Expenses (Quarterly) | 69.71M |
| EPS Diluted (Quarterly) | -0.978 |
| Earnings Yield | -21.89% |
| Normalized Earnings Yield | -21.89 |